Lang Xia

The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study

Y. She, Junqi Wu, Lei Zhang, 2022, Cancer Immunology, Immunotherapy.

The IASLC grading system for invasive pulmonary adenocarcinoma: a potential prognosticator for patients receiving neoadjuvant therapy

Yue Zhao, Y. She, Junqi Wu, 2023, Therapeutic advances in medical oncology.

The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study

Y. She, Junqi Wu, Lei Zhang, 2022, Cancer Immunology, Immunotherapy.

Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study

Y. She, Junqi Wu, Lei Zhang, 2022, Cancer Immunology, Immunotherapy.

Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy

D. Xie, Liping Zhang, L. Hou, 2022, Histopathology.